J Korean Ophthalmol Soc.  2020 Sep;61(9):. 10.3341/jkos.2020.61.9.1048.

Clinical Features of Eyes with Polypoidal Choroidal Vasculopathy and No Recurrence Over One Year

  • 1Department of Ophthalmology and Visual Science, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 2Apgujung St. Mary's Eye Center, Seoul, Korea


We here describe the clinical features of eyes with polypoidal choroidal vasculopathy (PCV) that exhibited good visual acuity (VA) over one year without additional treatment.
Patients newly diagnosed with PCV who received anti-vascular endothelial growth factor injections three times per month, with or without photodynamic therapy, were retrospectively reviewed. We divided the patients into those who maintained good VA for over one year (nonrecurrent group, 47 eyes) and those who required further treatment because of recurrence (recurrent group, 54 eyes). We compare the baseline characteristics including optical coherence tomographic and indocyanine green angiographic data of the two groups.
The nonrecurrent group (initially treated via single or combination therapy) exhibited a smaller greatest linear dimension (GLD) (p < 0.001), fewer polyps (p < 0.001), and no pigment epithelial detachment (PED) at baseline (p = 0.003) compared to the recurrent group. Logistic regression revealed that a lower GLD (p = 0.002), fewer polyps (p= 0.013), and absence of PED (p = 0.025) were associated with a favorable prognosis.
PCV eyes with smaller lesions, fewer polyps, and no PED at baseline exhibited no recurrence with good VA for over one year after treatment. Such patients can be expected to show a benign course after treatment.


Anti-vascular endothelial growth factor; Photodynamic therapy; Polypoidal choroidal vasculopathy
Full Text Links
  • JKOS
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr